New breast cancer trial aims to spare heart toxicity with smart drug strategy

NCT ID NCT07372079

Not yet recruiting Disease control Sponsor: Tianjin Medical University Cancer Institute and Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests a new antibody drug (QL1706) combined with chemotherapy in 40 people with early triple-negative breast cancer. The treatment is tailored based on how the tumor responds after initial cycles, with the goal of avoiding certain heart-damaging drugs if possible. The study aims to see if this approach can improve complete tumor disappearance before surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QL1706 (iparomlimab and tuvonralimab injection) combined with chemotherapy (albumin-bound paclitaxel, cisplatin, epirubicin, cyclophosphamide)
What this could lead to: If successful, this could offer a more personalized treatment for early triple-negative breast cancer, potentially reducing heart damage from chemotherapy while maintaining effectiveness.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to all patients. The combination therapy may cause significant side effects, and the response-guided approach may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER IMMUNE CHECKPOINT INHIBITORS NEOADJUVANT THERAPY QL1706

Contacts and locations

Locations

Tianjin Medical University Cancer Institute & Hospital

Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.